Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocbrutinib in Relapsing-Remitting Multiple Sclerosis (Phase IIa)
CTR20254904Phase 2Active
- Sponsor
- Lupeng Pharmaceutical
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rocbrutinib in multiple sclerosis (MS), sponsored by Lupeng Pharmaceutical. Started Feb 2026; status: active.
02
Drugs
rocbrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on CTR20254904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254904.